摘要
目的:探讨2种药物治疗方案对社区获得性肺炎的经济效果。方法:采用回顾性研究方法,选择88例社区获得性肺炎患者,分别给予头孢哌酮钠/舒巴坦钠组(A组)、左氧氟沙星组(B组),观察2组疗效并进行成本-效果分析。结果:A组与B组成本分别为1803·91、1599·81元(P>0·05),有效率分别为95·0%、100·0%(P>0·05),成本-效果比分别为1898·85、1599·81。结论:B组方案优于A组方案。
OBJECTIVE： To evaluate the cost- effectiveness of two therapeutic schemes in the treatment of community acquired pneumonia. METHODS： A retrospective study was conducted in which a total of 88 cases with community acquired pneumonia were randomly assigned to receive cefoperazone sodium/sulbactam sodium （Group A） or levofloxacin （Group B） . The therapeutic effects were monitored and the cost - effectiveness analyses were conducted on the two group. RESULTS： The cost was 1 803.91 yuan in Group A versus 1 599.81 yuan in Group B （P 〉 0.05）; the effective rates were 95.0% versus 100.0% （P 〉0.05） and the cost -effectiveness ratios were 1 898.85 and 1 599.81, respectively. CONCLUSION： Levoflocaxin is superior to cefoperazone sodium/sulbactam sodium for community acquired pneumonia.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第8期566-568,共3页
China Pharmacy
关键词
社区获得性肺炎
头孢哌酮/舒巴坦钠
左氧氟沙星
成本-效果分析
Community acquired pneumonia
Cefoperazone sodium/sulbactam sodium
Levofloxacin
Cost effectiveness analysis
